Key Points
- Vaxcyte EVP Jim Wassil sold 2,250 shares for $137,025 at an average price of $60.90 under a pre-arranged Rule 10b5-1 plan. He retained 145,435 shares, a 1.52% reduction in his holdings.
- Vaxcyte reported quarterly EPS of -$1.99, beating the consensus estimate of -$2.11 by $0.12.
- Analysts’ consensus rating is “Moderate Buy,” with an average price target of $110.50; institutional investors and hedge funds own 96.78% of the stock.
Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) EVP Jim Wassil sold 2,250 shares of the company's stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $60.90, for a total value of $137,025.00. Following the completion of the sale, the executive vice president owned 145,435 shares in the company, valued at $8,856,991.50. This trade represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jim Wassil also recently made the following trade(s):
- On Monday, October 5th, Jim Wassil sold 18,000 shares of Vaxcyte stock. The stock was sold at an average price of $86.74, for a total value of $1,561,320.00.
- On Thursday, October 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.67, for a total value of $127,507.50.
- On Wednesday, September 9th, Jim Wassil sold 1,334 shares of Vaxcyte stock. The shares were sold at an average price of $59.52, for a total transaction of $79,399.68.
- On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The shares were sold at an average price of $61.16, for a total transaction of $84,461.96.
- On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The stock was sold at an average price of $61.07, for a total transaction of $212,340.39.
Vaxcyte Stock Performance
PCVX opened at $65.68 on Thursday. The firm has a market cap of $9.77 billion, a price-to-earnings ratio of -8.61 and a beta of 1.31. The firm's 50-day simple moving average is $61.64 and its 200-day simple moving average is $57.16. Vaxcyte, Inc. has a twelve month low of $39.87 and a twelve month high of $90.75.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($1.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.11) by $0.12. During the same quarter in the prior year, the company earned ($1.56) EPS. As a group, sell-side analysts anticipate that Vaxcyte, Inc. will post -7.47 EPS for the current fiscal year.
Institutional Trading of Vaxcyte
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. New York Life Investment Management LLC lifted its stake in Vaxcyte by 19.7% in the third quarter. New York Life Investment Management LLC now owns 21,011 shares of the company's stock valued at $1,196,000 after buying an additional 3,451 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Vaxcyte by 6.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 7,808 shares of the company's stock valued at $438,000 after buying an additional 444 shares during the period. Candriam S.C.A. boosted its holdings in shares of Vaxcyte by 115.0% in the third quarter. Candriam S.C.A. now owns 447,260 shares of the company's stock valued at $25,542,000 after buying an additional 239,206 shares during the period. Covestor Ltd increased its position in shares of Vaxcyte by 31.1% during the third quarter. Covestor Ltd now owns 939 shares of the company's stock worth $53,000 after acquiring an additional 223 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Vaxcyte during the third quarter worth $1,270,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several analysts have recently weighed in on PCVX shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vaxcyte in a report on Friday, October 2nd. Guggenheim lifted their target price on shares of Vaxcyte from $116.00 to $125.00 and gave the company a "buy" rating in a research note on Monday, October 5th. BTIG Research reissued a "buy" rating and issued a $89.00 target price on shares of Vaxcyte in a report on Monday, October 5th. Zacks Research upgraded Vaxcyte from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 12th. Finally, Needham & Company LLC increased their price target on Vaxcyte from $110.00 to $122.00 and gave the stock a "buy" rating in a research report on Monday, October 5th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Vaxcyte currently has an average rating of "Moderate Buy" and an average target price of $110.50.
View Our Latest Report on PCVX
Vaxcyte Company Profile
(
Get Free Report)
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection.
Vaxcyte's lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
